Epithelial sodium channel subunit mRNAs (ENaC mRNAs)

Epithelial sodium channel (ENaC) subunit mRNAs, primarily SCNN1A, SCNN1B, and SCNN1G, are the genetic templates for the heterotrimeric ENaC protein complex, which serves as the rate-limiting step for sodium absorption across epithelial membranes (Mall, 2020). In the respiratory tract, ENaC plays a vital role in regulating the volume of the airway surface liquid (ASL); however, in diseases like Cystic Fibrosis, ENaC becomes hyperactive due to the loss of CFTR-mediated regulation, leading to ASL dehydration and impaired mucus clearance (Han et al., 2021). Therapeutic strategies targeting these mRNAs utilize antisense oligonucleotides (ASOs) or small interfering RNAs (siRNAs) to downregulate the expression of ENaC subunits, thereby reducing sodium hyperabsorption and restoring lung hydration (Ionis Pharmaceuticals, 2021). This genetic approach aims to provide a more durable therapeutic effect and localized action within the lungs compared to traditional small-molecule inhibitors like amiloride, which are limited by short half-lives and the risk of systemic hyperkalemia (Arrowhead Pharmaceuticals, 2020). By specifically reducing the mRNA transcript levels, these therapies offer a precision medicine approach to treating obstructive lung diseases and other sodium-transport disorders.

Other names

SCNN1A mRNASCNN1B mRNASCNN1G mRNAAmiloride-sensitive sodium channel subunit mRNAsSodium channel epithelial 1 alpha subunit mRNASodium channel epithelial 1 beta subunit mRNASodium channel epithelial 1 gamma subunit mRNA

Antisense oligonucleotide-mediated RNase H1 cleavage of mRNA and RNA interference (RNAi)-mediated mRNA degradation to reduce ENaC protein expression.